Research Article

In Vitro Sensitivity of Paired Leishmania (Viannia) braziliensis Samples Isolated before Meglumine Antimoniate Treatment and after Treatment Failure or Reactivation of Cutaneous Leishmaniasis

Cibele Baptista, 1 Luciana de Freitas Campos Miranda, 2 Maria de Fátima Madeira, 2 Leonor Laura Pinto Leon, 3 Fátima Conceição-Silva, 4 and Armando de Oliveira Schubach 2

1 Núcleo de Biossegurança, Bio-Manguinhos, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, RJ, Brazil
2 Laboratório de Pesquisa Clínica e Vigilância em Leishmanioses, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, 21040-900 Rio de Janeiro, RJ, Brazil
3 Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, 21040-360 Rio de Janeiro, RJ, Brazil
4 Laboratório de Imunoparasitologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, 21040-360 Rio de Janeiro, RJ, Brazil

Correspondence should be addressed to Luciana de Freitas Campos Miranda; luciana.freitas@ini.fiocruz.br

Received 12 December 2014; Accepted 9 January 2015

Academic Editor: Robert Pichler

Copyright © 2015 Cibele Baptista et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study evaluated the in vitro sensitivity of paired Leishmania braziliensis samples isolated from the same patient before pentavalent antimonial treatment (Sample A) and after treatment failure or cutaneous leishmaniasis reactivation (Sample B) in patients undergoing intralresional administration or injections (5 mg Sb V/kg/d) of meglumine antimoniate. Fourteen samples from 7 patients were studied. After 24 h of drug exposure, 50% lethal dose (LD 50 ) values for promastigotes ranged from 0.37 mg/mL to 5.86 mg/mL for samples obtained before treatment (A) and 0.89 mg/mL to 7.80 mg/mL for samples obtained after treatment (B). After 48 h, LD 50 values ranged from 0.37 mg/mL to 5.75 mg/mL and 0.70 mg/mL to 7.68 mg/mL for A and B samples, respectively. After 48 h, LD 50 values for amastigotes ranged from 11.7 to 44.3 μg/mL for A samples and 13.7 to 52.7 μg/mL for B samples. Of 7 patients, 1 discontinued treatment and 6 were cured after retreatment with amphotericin B (4 cases) or meglumine antimoniate (2 cases). Overall the B samples had higher LD 50 values than A samples; however the difference was not significant. These results do not support the hypothesis that low-dose and intralresional treatments induce selection of resistant parasites in vitro and suggest that other factors may influence therapeutic outcome in patients with poor response to initial treatment.

1. Introduction

American cutaneous leishmaniasis (ACL) is caused by protozoan species of the genus Leishmania transmitted by the bite of infected phlebotomine sandflies [1]. In Brazil, Leishmania (Viannia) braziliensis is the main etiologic agent of cutaneous, mucosal, and mucocutaneous ACL [2–4]. Leishmania sp. is a heteroxenous parasite with two developmental forms: amastigotes and promastigotes. Amastigotes are rounded and intracellular, and they are found in the parasitophorous vacuole of phagocytic mononuclear cells, especially macrophages, of vertebrate hosts. Promastigotes, in contrast, are elongated with free flagellum, and they develop in the gut of the sandfly insect vector as well as in axenic cultures. Both forms are used in in vitro assays to assess therapeutic sensitivity [5].

Pentavalent antimonials (Sb V) are the drugs of choice for treatment of cutaneous leishmaniasis (CL), with recommended doses of 10–20 mg Sb V/kg/d for 20 days [6]. For many years, the Evandro Chagas National Institute of Infectious Disease/Oswaldo Cruz Foundation (INI/FIOCRUZ) in Rio de Janeiro, Brazil, has administered 5 mg Sb V/kg/d
intramuscularly continuously or in series [4, 7–9] or via intralesional (IL) administration [10, 11]. Treatment response is usually favorable in Rio de Janeiro regardless of regimen. Nevertheless, treatment failure or reactivation of skin lesions after treatment has been reported in various endemic areas [5, 6, 12–14]. Authors have associated treatment failure or reactivation with host immune response, pharmacological factors such as drug absorption and perfusion at the infection site, and, especially, factors associated with parasite resistance to antimonials [15, 16].

Antimonial resistance has been reported [16–19] and it should be considered a significant problem due to the limited drug arsenal for treatment of this disease [20]. Leishmania (Leishmania) donovani isolates resistant to Sbv have been identified in regions of India and Nepal. Resistance has been reported recently in the New World [21]. Efforts have been made to compare clinical treatment response to in vitro antimonial sensitivity. However, available in vitro techniques cannot detect L. braziliensis resistance with certainty [5, 22, 23].

In this study, we evaluated the in vitro susceptibility of L. braziliensis amastigotes and promastigotes to meglumine antimoniate by comparing paired isolates obtained from the same patient before and after treatment failure or reactivation of skin lesions.

2. Materials and Methods

2.1. Patients and Samples. Eligible patients included those undergoing CL treatment of 30 continuous intramuscular doses of 5 mg Sbv/kg/d meglumine antimoniate, 10-dose intramuscular series with 10 days rest between sets (low dose), or IL administration of the volume necessary to infiltrate the base of the lesion, with approximately 15 days between treatment applications. Two Leishmania (V.) braziliensis samples were isolated from the same lesion at diagnosis before treatment (Sample A) and after treatment failure or lesion reactivation (Sample B).

Treatment failure was defined as no progressive lesion healing after treatment completion. Reactivation was defined as lesion reactivation after apparently successful initial treatment with signs of healing.

All patients were from the state of Rio de Janeiro and attended the Leishmaniasis Outpatient Clinic at INI/FIOCRUZ.

The study was approved by the Ethics Committee in Research of the INI/FIOCRUZ. All patients signed a consent form prior to clinical evaluation to provide lesion samples for culture. Lesion fragments were seeded in Novy-MacNeal-Nicolle (NNN) biphasic medium and Schneider’s Drosophila Medium (Sigma, St. Louis, Missouri) supplemented with 10% fetal calf serum (FCS) and antibiotics (200 U penicillin + 100 µg streptomycin). Isolates were identified by isoenzyme electrophoresis and maintained in culture only through the fifth passage to maintain parasite infectivity.

2.2. Drug. Meglumine antimoniate (Glucantime, Sanofi-Aventis), Lot 604898, available in 5 mL ampoules containing 81 mg Sbv/mL, was provided by the Health Surveillance Department of the Ministry of Health, Brazil. The drug was diluted in Schneider’s or RPMI-1640 (Gibco, BRL, Grand Island, NY, USA) culture medium for use in in vitro assays. Promastigotes and amastigotes from each sample were used to evaluate the in vitro drug sensitivity.

2.3. Promastigote Assays. First, sample growth curves were generated: test tubes (16 × 150 mm) containing 4 mL Schneider medium supplemented with 10% FCS and antibiotics were inoculated with 1 × 10⁷ parasites/mL and stored at 26–28°C. Quantification was performed in triplicate at 24 h intervals for 5 days using a Neubauer chamber and Trypan Blue staining.

Based on these growth curves, parasites in stationary phase and before their fifth passage in culture were used for sensitivity tests. Assays were performed in 96-well culture plates and evaluated after 24 and 48 h exposure to meglumine antimoniate. A and B samples were evaluated on the same plate and at the same time. A 100 µL suspension containing 1 × 10⁶ parasites diluted in Schneider medium was placed in each well of a plate containing the same volume of drug (100 µL). Twofold serial dilutions of meglumine antimoniate were used, starting at 8.1 mg Sbv/mL to 3.955 µg Sbv/mL. The plates were incubated in a biological incubator (26–28°C), and the parasites were quantified after 24 and 48 h using a Neubauer chamber and Trypan Blue staining. A and B parasite samples not exposed to drug were used as controls. The experiment was performed in triplicate and values compared to no-drug controls. The dose of drug required for 50% parasite mortality (LD50) was determined from these measurements and calculated using Microsoft Excel software as described in Machado et al. [24].

2.4. Amastigote Assays. Amastigote sensitivity tests were conducted by in vitro infection of cultured murine macrophages. Briefly, the macrophages were isolated from peritoneal cavity of outbred Swiss Webster mice by washing with about 10 mL of RPMI-1640 medium using a syringe. These cells were plated (2 × 10⁶ macrophages/mL) in chamber slides (Lab-Tec, Nalge Nunc International) and then incubated for 2 h at 37°C in a 5% CO2 atmosphere. Nonadherent cells were removed by washing with RPMI-1640 medium, supplemented with 10% FCS. Cells were maintained under the same culture conditions for 24 h before infection. After this period, 5–10 promastigotes (Samples A and B) per macrophage were added. After 2 h, free parasites were removed by washing the monolayers with serum-free medium and the culture medium (RPMI + 10% FCS) was renewed. The drug at concentrations of 20, 40, and 80 µg Sbv/mL, diluted in the same medium, was added 24 h after infection, with the infection kinetics evaluated at 24, 48, and 72 h. At each time point, the slides were washed with phosphate buffered solution (PBS) pH 7.2 (37°C), fixed with methyl alcohol, and stained with Giemsa. Controls were macrophages infected with Samples A and B without meglumine antimoniate. A total of 100 random macrophages at each time point from Samples A and B and their respective controls were counted under an optical microscope to determine the effect of drug concentration.
The percentage (%) of infected cells and average number of amastigotes per cell were used to calculate infection rate. LD₅₀, expressed at 48 h of infection kinetics, was calculated from a dose-response graph using GraphPad Prism (version 5.04).

2.5. Statistical Analysis. SPSS Statistics for Windows (version 17.0) was used to perform the Wilcoxon test to compare promastigotes and amastigotes from A and B samples; P < 0.05 were considered statistically significant.

3. Results

A total of 14 paired samples (A and B) from 7 patients were included in this study. Patient ages ranged from 18 to 71 years; 4 were women. Following initial treatment, treatment failure and reactivation were observed in 5 and 2 patients, respectively. Of these 7 patients, 1 patient discontinued treatment and 6 were cured after retreatment with amphotericin B (4 cases) or meglumine antimoniate (2 cases).

The promastigote growth curve revealed a stationary phase between days 3 and 4; parasites on the third day of growth were therefore used in the assays. Paired samples (A and B) from the same patient showed similar growth profiles. Except for 1 patient, A samples showed the highest mean number of parasites at all points of the curve compared to B samples. However, there were no differences in their murine macrophage infective capacity.

We observed a drastic reduction in the percentage of infected cells and the average number of intracellular amastigotes in most samples and all drug concentrations (20, 40, and 80 μg/mL) at 72 h in the amastigote assays. For this reason, we used the 48 h time point to calculate LD₅₀.

Table 1 shows patient data regarding treatment and outcome, as well as LD₅₀ values for Sample A and B promastigotes and amastigotes forms. No significant difference was found between sample sensitivity levels.

4. Discussion

Pentavalent antimonials have been used to treat leishmaniasis with variable efficacy for about 70 years; resistance has been reported, particularly in visceral leishmaniasis [17, 18, 20]. In this study, we evaluated 14 paired *L. braziliensis* samples to verify the association between *in vitro* susceptibility and treatment outcome in patients treated with meglumine antimoniate.

Hypotheses on the development of parasite antimonial resistance gained prominence from publications by Grogl and colleagues [16, 25] based on results of *in vitro* assays that suggested that inadequate therapeutic doses could induce selection of antimonial-resistant parasite clones. This observation was strengthened by accounts of Sundar et al. [26] in India, where there was a failure to control the use of antimonials for treatment of visceral leishmaniasis. Lira et al. [27] showed that *L. donovani* isolated from patients in India that were nonresponsive to antimonials had 3-fold higher LD₅₀ values than isolates from drug-responsive patients.

In another study using paired samples, samples isolated after treatment showed the higher LD₅₀ values compared to samples taken before treatment [28]. Despite speculation, there is still no definitive marker for parasite antimonial resistance [29].

The patients in our study were diagnosed, treated, and followed up at INI/FIOCRUZ, which has a long and successful treatment history using intramuscular injections (5 mg SbV/kg/d) or IL administration of meglumine antimoniate [4, 8–11]. Of 7 patients enrolled in this study, 5 were treated with intramuscular administration of the low-dose regimen and 2 received IL treatment. Retreatments were administered at the discretion of the treating physician. Regarding therapeutic outcomes, 1 patient stopped treatment. Two patients were cured with the same treatment regimen initially employed (5 mg SbV/kg/d), and 4 patients were cured with retreatment using amphotericin B [6].

Because other factors may be involved, it is often difficult to associate therapeutic failure only to parasite resistance [22, 23, 30]. However, knowledge of characteristics of parasites isolated in different situations can contribute important elements to this discussion.

Parasite species and subpopulations with genetic polymorphisms may also influence clinical course and treatment response. *L. braziliensis* is known to consist of populations with high genetic variability that can cause predominantly cutaneous and mucosal lesions. However, although different clinical patterns and varied treatment response are reported in the state of Rio de Janeiro, the *L. braziliensis* genetic profile is homogeneous [31]. The samples in this study also had homogeneous phenotypic profiles, without isozyme variation.

Growth curves were generated for all samples to determine timing of the stationary phase. This phase was reached between the third and fourth days of growth for all samples, as also reported by Moreira et al. [23]. Paired samples (A and B) from the same patient showed similar growth profiles. Growth profile differences could also be due to sample heterogeneity; further consideration of *in vitro* growth parameters is necessary [32]. An interesting observation in our study was that, except for 1 patient, A samples showed the largest average number of parasites at all points of the curve compared to B samples. This finding suggests that prior exposure to treatment could impair the ability of promastigotes to multiply *in vitro*. However, A and B samples showed no difference in their ability to infect murine macrophages.

The variable *in vitro* susceptibility of promastigotes and amastigotes may be related to experimental conditions or inherent characteristics of evolutionary forms. A significant limitation of using promastigotes in these tests is that they are not the evolutionary form in the vertebrate host. Similar to our findings, others have reported promastigotes to be resistant to meglumine antimoniate, requiring higher drug doses than amastigotes [5]. Vermeersch et al. [33] propose that an intracellular amastigote model should be the standard reference for *in vitro* sensitivity testing. Although our results revealed large heterogeneity in LD₅₀ values, they generally agree with other studies using promastigotes [5, 32]. It was not possible to establish a relationship between therapeutic
Table 1: Clinical outcome related to treatment of tegumentary leishmaniasis, in which paired *Leishmania braziliensis* samples were analyzed by *in vitro* sensitivity testing. LD$_{50}$ values for amastigotes ($\mu$g Sb$^V$/mL) and promastigotes (mg Sb$^V$/mL) forms obtained before treatment (A) and after treatment failure or reactivation (B) are shown.

| Patient code | Time until diagnosis | Lesion number | 1st treatment/clinical outcome | Interval between isolation of samples A and B | Retreatments/clinical outcome | Amastigotes LD$_{50}$ ($\mu$g Sb$^V$/mL) 48h | Promastigotes LD$_{50}$ (mg Sb$^V$/mL) 24h | Promastigotes LD$_{50}$ (mg Sb$^V$/mL) 48h |
|--------------|---------------------|---------------|-------------------------------|-----------------------------------|---------------------------------|----------------|----------------|----------------|
| 1            | 18                  | 1             | 5 mg Sb$^V$ series—30 doses/TF | 21                                | 2nd T: 5 mg Sb$^V$ series       | 1797           | 1794           | 3.06           | 6.98           | 1.08           | 5.82           |
|              |                     |               |                               |                                   | 3rd T: IL                       |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | 4th T: Amp B                    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |
| 2            | 3                   | 1             | IL—2 doses/reactivation       | 13                                | 2nd T: IL                       | 11.7            | 13.7           | 4.38           | 0.89           | 5.75           | 1.37           |
|              |                     |               |                               |                                   | 3rd T: Amp B                    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |
| 3            | 1.5                 | 5             | 5 mg Sb$^V$ series—30 doses/TF | 14                                | 2nd T: 5 mg Sb$^V$ continuous    | 11.7            | 14.1           | 0.37           | 1.78           | 0.37           | 0.70           |
|              |                     |               |                               |                                   | 3rd T: 5 mg Sb$^V$ continuous    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |
| 4            | 2                   | 2             | 5 mg Sb$^V$ continuous—30 doses/TF | 07                                | 2nd T: 5 mg Sb$^V$ continuous    | 14.0            | 15.2           | 5.20           | 6.79           | 3.04           | 5.35           |
|              |                     |               |                               |                                   | 3rd T: 15 mg Sb$^V$ + pentoxifylline | Treatment dropout |                 |                |                |                |                |
|              |                     |               |                               |                                   |                                 |                 |                 |                |                |                |                |
| 5            | 1.5                 | 1             | 5 mg Sb$^V$ continuous—38 doses/TF | 18                                | 2nd T: IL                       | 44.3            | 52.7           | 5.86           | 7.80           | 3.28           | 7.68           |
|              |                     |               |                               |                                   | 3rd T: 5 mg Sb$^V$ continuous    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | 4th T: 5 mg Sb$^V$ continuous    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | 5th T: Amp B                    |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |
| 6            | Unknown             | 1             | 5 mg Sb$^V$ continuous—45 doses/reactivation | 27                                | 2nd T: 5 mg Sb$^V$ series       | 16.1            | 33.7           | 4.53           | 7.46           | 3.00           | 5.61           |
|              |                     |               |                               |                                   | 3rd T: 5 mg continuous          |                 |                 |                |                |                |                |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |
| 7            | 1.5                 | 1             | IL—8 doses/TF                 | 13                                | 2nd T: Amp B                    | 16.8            | 16.3           | 5.05           | 7.70           | 1.04           | 3.56           |
|              |                     |               |                               |                                   | Healing                         |                 |                 |                |                |                |                |

*Time in months; T (treatment); IL (intralosomal administration); Amp B (amphotericin B); TF (treatment failure); **P value = 0.063; ***P value = 0.176; ****P value = 0.128.
response and in vitro sensitivity data with promastigotes because 2 of 4 patients with increased Sample B LD50 recovered after meglumine antimoniate retreatment. This suggests that other variables may have positive or negative influences in this context. Zauli-Nascimento et al. [21] also found no correlation between in vitro results and therapeutic response in patients with ACL.

In addition to the large variation of LD50 absolute values in both promastigotes and amastigotes, we found that B samples had higher LD50 values compared to A samples. This result might suggest that samples isolated after reactivation are less sensitive to meglumine antimoniate in vitro; however, the difference was not statistically significant. These results do not support the hypothesis that low dose or IL treatments induce selection of resistant parasites in vitro. Other factors such as immune response to infection may influence treatment outcome in patients with poor response to initial treatment; correlations should therefore be treated with caution.

Zauli-Nascimento et al. [21] also found no correlation between in vitro results and therapeutic response in patients with ACL. According to these authors, there is no evidence of primary parasite resistance to SbV in Brazil, unlike reports with ACL. Taking into account these results and therapeutic response in patients with ACL, according to these authors, there is no evidence of primary parasite resistance to SbV in Brazil, unlike reports with ACL.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study received financial support from the National Council of Research Development (CNPq) and Kinder Institute of Brazil (IKB). A. Schubach and M. F. Madeira hold a grant for productivity in research (CNPq). A. Schubach is a scientist of the authors’ state and M. F. Madeira is a young scientist of their state (FAPERJ).

References

[1] WHO, “Control of the leishmaniases,” Technical Report Series 949, World Health Organization, Geneva, Switzerland, 2010.

[2] M. C. de A. Marzochi and K. B. F. Marzochi, “Tegumentary and visceral leishmaniases in Brazil—emerging anthropozooonosis and possibilities for their control,” Cadernos de Saúde Pública, vol. 10, supplement 2, pp. 359–375, 1994.

[3] M. P. de Oliveira-Neto, M. S. Mattos, M. A. Perez et al., “American tegumentary leishmaniasi (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics,” International Journal of Dermatology, vol. 39, no. 7, pp. 506–514, 2000.

[4] A. de Oliveira Schubach, K. B. Feldman Marzochi, J. Soares Moreira et al., “Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 38, no. 3, pp. 213–217, 2005.

[5] R. B. G. Azeredo-Coutinho, S. C. F. Mendonça, H. Callahan, A. C. Portal, and M. Grögl, “Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis,” Journal of Parasitology, vol. 93, no. 3, pp. 688–693, 2007.

[6] Ministério da Saúde, Ed., Manual de Vigilância da Leishmaniose Tegumentar Americana, Editora do Ministério da Saúde, Brasilia, Brazil, 2nd edition, 2010.

[7] M. P. Oliveira-Neto, A. Schubach, M. L. Araujo, and C. Pirmerez, “High and low doses of antimony (SbV) in American cutaneous leishmaniasis. A five years follow-up study of 15 patients,” Memórias do Instituto Oswaldo Cruz, vol. 91, no. 2, pp. 207–209, 1996.

[8] M. P. Oliveira-Neto, A. Schubach, M. Mattos, S. C. Gonçalves-Costa, and C. Pirmerez, “A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years),” American Journal of Tropical Medicine and Hygiene, vol. 57, no. 6, pp. 651–655, 1997.

[9] M. P. Oliveira-Neto, A. Schubach, M. Mattos, S. C. Gonçalves-Costa, and C. Pirmerez, “Treatment of American cutaneous leishmaniasis: a comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens,” Pathologie Biologie, vol. 45, no. 6, pp. 496–499, 1997.

[10] M. P. Oliveira-Neto, A. Schubach, M. Mattos, S. C. Gonçalves da Costa, and C. Pirmerez, “Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil—an area of Leishmania (V.) braziliensis transmission,” International Journal of Dermatology, vol. 36, no. 6, pp. 463–468, 1997.

[11] É. D. C. Ferreira E Vasconcellos, M. I. Fernandes Pimentel, A. De Oliveira Schubach et al., “Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006),” American Journal of Tropical Medicine and Hygiene, vol. 87, no. 2, pp. 257–260, 2012.

[12] A. M. Rodrigues, M. Hueb, T. A. Santos, and C. J. Fontes, “Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate,” Revista da Sociedade Brasileira de Medicina Tropical, vol. 39, no. 2, pp. 139–145, 2006.

[13] R. Rojas, L. Valderrama, M. Valderrama, M. X. Varona, M. Ouellette, and N. G. Saravia, “Resistance to antimony and treatment failure in human Leishmania (Viannia) infection,” Journal of Infectious Diseases, vol. 193, no. 10, pp. 1375–1383, 2006.

[14] D. O. Santos, C. E. R. Coutinho, M. F. Madeira et al., “Leishmaniasis treatment—a challenge that remains: a review,” Parasitology Research, vol. 103, no. 1, pp. 1–10, 2008.

[15] S. L. Croft, K. Seifert, and V. Yardley, “Current scenario of drug development for leishmaniasis,” Indian Journal of Medical Research, vol. 123, no. 3, pp. 399–410, 2006.

[16] M. Grögl, T. N. Thomason, and E. D. Franke, “Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease,” The American Journal of Tropical Medicine and Hygiene, vol. 47, no. 1, pp. 117–126, 1992.

[17] S. Sundar, D. K. More, M. K. Singh et al., “Failure of pentavalent antimony in visceral leishmaniasis in India: report from the
center of the Indian epidemic," Clinical Infectious Diseases, vol. 31, no. 4, pp. 1104–1107, 2000.

[18] P. J. Guerin, P. Olliaro, S. Sundar et al., "Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda," The Lancet Infectious Diseases, vol. 2, no. 8, pp. 494–501, 2002.

[19] K. Aît-Oudhia, E. Gazanion, D. Sereno et al., "In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure," Veterinary Parasitology, vol. 187, no. 3-4, pp. 386–393, 2012.

[20] J. Mishra, A. Saxena, and S. Singh, "Chemotherapy of leishmaniasis: past, present and future," Current Medicinal Chemistry, vol. 14, no. 10, pp. 1153–1169, 2007.

[21] C. Baptista, A. O. Schubach, M. F. Madeira et al., "Leishmania (Viannia) braziliensis genotypes identified in lesions of patients with atypical or typical manifestations of tegumentary leishmaniasis: evaluation by two molecular markers," Experimental Parasitology, vol. 121, no. 4, pp. 317–322, 2009.

[22] H. L. Callahan, A. C. Portal, R. Devereaux, and M. Grogl, "An axenic amastigote system for drug screening," Antimicrobial Agents and Chemotherapy, vol. 41, no. 4, pp. 818–822, 1997.

[23] M. Vermeersch, R. I. Da Luz, K. Toté, J.-P. Timmermans, P. Cos, and L. Maes, "In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences," Antimicrobial Agents and Chemotherapy, vol. 53, no. 9, pp. 3855–3859, 2009.